Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2007-11-26
2011-11-01
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C530S388230, C530S387100
Reexamination Certificate
active
08048422
ABSTRACT:
Anti-Tweak antibodies are described.
REFERENCES:
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5693762 (1997-12-01), Queen
patent: 5859205 (1999-01-01), Adair
patent: 5885793 (1999-03-01), Griffiths et al.
patent: 6207642 (2001-03-01), Wiley
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6727225 (2004-04-01), Wiley
patent: 6824773 (2004-11-01), Wiley
patent: 6943146 (2005-09-01), Jakubowski et al.
patent: 7087725 (2006-08-01), Browning et al.
patent: 7109298 (2006-09-01), Browning et al.
patent: 7129061 (2006-10-01), Browning et al.
patent: 7169387 (2007-01-01), Rennert
patent: 7208151 (2007-04-01), Browning et al.
patent: 7482430 (2009-01-01), Wiley
patent: 7495086 (2009-02-01), Kim et al.
patent: 7507807 (2009-03-01), Wiley
patent: 7517962 (2009-04-01), Wiley
patent: 7566769 (2009-07-01), Browning et al.
patent: 7579001 (2009-08-01), Rennert
patent: 7695934 (2010-04-01), Browning
patent: 7731963 (2010-06-01), Browning
patent: 2002/0015703 (2002-02-01), Rennert
patent: 2005/0007957 (2005-01-01), Ibaraki et al.
patent: 2005/0008625 (2005-01-01), Balint et al.
patent: 2005/0008636 (2005-01-01), Rennert
patent: 2006/0003932 (2006-01-01), Jakubowski et al.
patent: 2006/0240004 (2006-10-01), Burkly et al.
patent: 2006/0252122 (2006-11-01), Browning et al.
patent: 2007/0110745 (2007-05-01), Rennert
patent: 2007/0280940 (2007-12-01), Winkles et al.
patent: 2008/0008714 (2008-01-01), Browning et al.
patent: 2008/0187544 (2008-08-01), Burkly et al.
patent: 2008/0279853 (2008-11-01), Burkly et al.
patent: 2008/0286271 (2008-11-01), Ashkenazi et al.
patent: 2008/0292622 (2008-11-01), Burkly et al.
patent: 2009/0068102 (2009-03-01), Burkly et al.
patent: 2009/0124993 (2009-05-01), Burkly et al.
patent: 2009/0311313 (2009-12-01), Burkly et al.
patent: 2010/0061985 (2010-03-01), Rennert
patent: 1566636 (2005-08-01), None
patent: WO 98/05783 (1998-02-01), None
patent: WO 98/35061 (1998-08-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/42073 (2000-07-01), None
patent: WO 01/45730 (2001-06-01), None
patent: WO 02/22166 (2002-03-01), None
patent: WO 03/086311 (2003-10-01), None
patent: WO 2005/080972 (2005-09-01), None
patent: WO 2006/047172 (2006-05-01), None
patent: WO 2006/052926 (2006-05-01), None
patent: WO 2006/088890 (2006-08-01), None
patent: WO 2006/089095 (2006-08-01), None
patent: WO 2006/096487 (2006-09-01), None
patent: WO 2006/122187 (2006-11-01), None
patent: WO 2006/130429 (2006-12-01), None
patent: WO 2006/138219 (2006-12-01), None
patent: WO 2008/048924 (2008-04-01), None
Portolano et al. Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by Human H an L chain “Roulette”. J. Immunol. vol. 150(3):880-887 (1993).
Clackson et al. Making antibody fragments using phage display libraries. Nature. vol. 352:624-628 (1991).
Pascalis et al. Grafting of “Abbreviated” Complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. The Journal of Immunology, 169:3076-3084 (2002.).
Bose et al. Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection. Immunology, vol. 116:172-183 (2005).
David et al. A study of the structural correlates of affinity maturation: Antibody affinity as a function of chemical interactions, structural plasticity and stability. Molecular Immunology, vol. 44:1342-1351 (2007).
Clark et al. Trends in antibody sequence changes during the somatic hypermutation process. The Journal of Immunology, vol. 177:333-340 (2006).
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody”, Mol. Immunol. 30:105-108 (1993).
Boucraut, J. et al., “Anti-TWEAK Monoclonal Antibodies Reduce CNS Immune Cell Infiltration and Severity of Experimental Autoimmune Encephalomyelitis” Meeting: Autoimmunity: Mechanisms and Novel Treatments, Mykonos, Greece, Oct. 8-13, 2003; Aegean Conference Series, vol. 12:Abstract 64, p. 89 (2003).
Campbell, S. et al., “Proinflammatory Effects of TWEAK/Fn14 Interactions in Glomerular Mesangial Cells”, J. Immunol. 176:1889-1898 (2006).
Campbell, S. et al., “The Role of Tweak/Fn14 in the Pathogenesis of Inflammation and Systemic Autoimmunity”, Frontiers in Bioscience 9:2273-2284 (2004).
Chicheportiche, Y. et al., “Proinflammatory Activity of TWEAK on Human Dermal Fibroblasts and Synoviocytes: Blocking and Enhancing Effects of Anti-TWEAK Monoclonal Antibodies”, Arthritis Res. 4(2):126-33 (2002). Epub Nov. 9, 2001.
Chothia et al., “Structural repertoire of the human VH segments”, J. Mol. Biol. 227:799-817 (1992).
Davies et al., “Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability”, Protein Eng. 9(6):531-537 (1996).
Desplat-Jego, S. et al., “Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis”, Clin. Immunol. 117(1):15-23 (2005).
Desplat-Jego, S. et al., “TWEAK Is Expressed by Glial Cells, Induces Astrocyte Proliferation and Increases EAE Severity”, J. Neuroimmunol. 133:116-123 (2002).
Donahue, P.J. et al., “TWEAK Is an Endothelial Cell Growth and Chemotactic Factor That Also Potentiates FGF-2 and VEGF-A Mitogenic Activity”, Arterioscler. Thromb. Vasc. Biol. 23:594-600 (2003).
Feng, S-L. Y., et al., “The Fn14 Immediate-Early Response Gene Is Induced During Liver Regeneration and Highly Expressed in Both Human and Murine Hepatocellular Carcinomas”, Am. J. Pathol. 156(4):1253-1261 (2000).
Hahm, K. et al., “TWEAK overexpression induces hyperplasia in liver and kidney”, FASEB J. 17:Abstract No. 471.5 (2003).
Han, H. et al., “Overexpression of FN14/TEAK receptor in pancreatic cancer”, Proc. Am. Assoc. Cancer Res Annual Meeting 46(Suppl. S):Abstract No. 2363 (Apr. 18, 2005).
Ho, D.H. et al., “Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Overexpression in HEK293 Cells Promotes Tumor Growth and Angiogenesis in Athymic Nude Mice”, Cancer Res. 64:8968-8972 (Dec. 15, 2004).
Jakubowski, A. et al., “Dual role for TWEAK in angiogenic regulation”, J. Cell Sci. 115(Pt 2):267-274 (Jan. 15, 2002).
Jakubowski, A. et al., “TWEAK induces liver progenitor cell proliferation”, J. Clin. Invest. 115(9):2330-2340 (Sep. 2005).
Jakubowski, A. et al., “TWEAK Synergizes With Basis Fibroblast Growth Factor to Induce Endothelial Cell Proliferation, Migration and Lumen Morphogenesis”, Abstracts for the 8th International TNF Congress on Tumor Necrosis Factor and Related Cytokines, Scand. J. Immunol. 51(Supplement 1): 62 (2000).
Kawakita, T. et al., “Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis”, Biochem. Biophys. Res. Commun. 318:726-733 (2004).
Lund et al., “Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG.”, J. Immun. 147:2657-2662 (1991).
Lynch, C. et al., “TWEAK Induces Proliferation in Endothelial Cells and Substitutes for EGF and Hydrocortisone in Culture”, J. Interferon Cytokine Res. 18:A-46 (1998).
Lynch, C.N. et al., “TWEAK Induces Angiogenesis and Proliferation of Endothelial Cells”, J. Biol. Chem. 274(13):8455-8459 (1999).
Michaelson, J.S. et al., “Tweak induces mammary epithelial branching morphogenesis”, Oncogene 24:2613-2624 (2005).
Morgan, A. et al., “The N-t
Burkly Linda C.
Garber Ellen
Lugovsky Alexey
Allen Marianne P
Biogen Idec MA Inc.
Deberry Regina M
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
LandOfFree
Tweak binding antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tweak binding antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tweak binding antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4309366